neuromyotonia

Syndrome versus discharge

Record whether neuromyotonia denotes the clinical syndrome, a localized manifestation, or an electrodiagnostic observation.

1. Does the recorded term identify a clinical syndrome or only neuromyotonic discharges? definition
2. Who assigned the label, on what date, and with what supporting assessment? provenance

Myotonia and cramp boundary

Preserve the reasoning that distinguishes neuromyotonia from primary muscle myotonia and less specific cramp or fasciculation presentations.

1. What examination and EMG observations support nerve-origin overactivity rather than muscle membrane myotonia? boundary
2. What evidence supports neuromyotonia beyond cramps or fasciculations alone? boundary

Resting and evoked activity

Document observed twitching, stiffness, cramps, and impaired relaxation separately from patient-reported sensations.

1. Which muscles show visible or palpable overactivity, and is the distribution focal, multifocal, or generalized? measurement
2. How do symptoms vary at rest, after voluntary contraction, and across the day? measurement

Stiffness and cramp interference

Establish reproducible measures of symptom interference and distinguish stiffness-limited activity from demonstrable weakness.

1. How frequently do cramps occur, and how much do stiffness and impaired relaxation interfere with walking, grip release, or sleep? measurement
2. Is reduced performance explained by pain or stiffness, objective weakness, or an unresolved combination? boundary

Waveform classification

Preserve neuromyotonic discharge findings alongside separately classified myokymic, fasciculation, and other activity.

1. Were neuromyotonic discharges identified, and what waveform characteristics supported that interpretation? measurement
2. Were myokymic discharges, fasciculations, or myotonic discharges distinguished explicitly in the report? boundary

Test context

Attach examination conditions and nerve conduction findings to the diagnostic conclusion.

1. Which symptomatic and asymptomatic muscles were sampled, and what symptom-suppressing treatments were being taken? provenance
2. Were stimulus-induced afterdischarges documented, absent, or not assessed? measurement
3. If clinical and electrodiagnostic findings disagree, what limitation or clinician-directed reassessment is recorded? action

Antibody interpretation

Capture CASPR2 and other relevant results with assay details; retain historical VGKC-complex wording without silently converting it into an antigen-specific result.

1. Which antigen-specific antibodies were tested, using what assay, specimen, and laboratory interpretation? provenance
2. Does a historical VGKC-complex result have documented antigen-specific follow-up? boundary
3. What evidence supports or limits the clinician's immune-mediated attribution? boundary

Etiologic links

Record family history, genetic interpretation, neuropathy, and associated disease evaluations without treating coexistence as proof of causation.

1. Do onset, family history, neuropathy findings, or a clinically interpreted genetic result support an inherited explanation? provenance
2. What evaluation for associated malignancy or autoimmune disease was undertaken, and why was it indicated? provenance
3. Is each linked disorder considered causal, associated, incidental, or unresolved? boundary

Broader syndrome review

Record whether associated features prompted assessment for a broader neurological syndrome, including Morvan syndrome, without automatically reclassifying the entry.

1. Are sweating changes, other autonomic symptoms, marked sleep disturbance, or cognitive and behavioral changes present? measurement
2. Has a clinician assessed whether these features belong to neuromyotonia, a broader syndrome, treatment effects, or another condition? boundary
3. What documented change should trigger expedited clinical reassessment? action

Targeted response

Separate symptom suppression, treatment of a proposed cause, adverse effects, and changes in associated disease.

1. What clinician-directed intervention was used, and did it target muscle overactivity, an attributed cause, or an associated disorder? action
2. How did cramps, stiffness, relaxation, and daily function change from the recorded baseline? measurement
3. What adverse effects, concurrent interventions, or natural fluctuations limit interpretation of the response? boundary

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these check these first hold for the sense of neuromyotonia this model covers, and on what evidence? provenance

Kinds and varieties

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these kinds and varieties hold for the sense of neuromyotonia this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these identifiers and schemes hold for the sense of neuromyotonia this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these real-world use hold for the sense of neuromyotonia this model covers, and on what evidence? provenance

Typical measurements

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these typical measurements hold for the sense of neuromyotonia this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these failure modes and hazards hold for the sense of neuromyotonia this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of neuromyotonia this model covers, and on what evidence? provenance